Authors
RA Kyle, BGM Durie, S Vincent Rajkumar, O Landgren, Joan Bladé, Giampaolo Merlini, Nicolaus Kröger, Hermann Einsele, DH Vesole, Meletios Dimopoulos, J San Miguel, H Avet-Loiseau, Roman Hajek, WM Chen, KC Anderson, Heinz Ludwig, Pieter Sonneveld, S Pavlovsky, Antonio Palumbo, PG Richardson, Bart Barlogie, Philip Greipp, Robert Vescio, Ingemar Turesson, Johan Westin, Mario Boccadoro
Publication date
2010/6
Source
Leukemia
Volume
24
Issue
6
Pages
1121-1127
Publisher
Nature Publishing Group
Description
Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of progression to multiple myeloma, Waldenstrom's macroglobulinemia, AL amyloidosis or a lymphoproliferative disorder is approximately 1% per year. Low-risk MGUS is characterized by having an M protein< 15 g/l, IgG type and a normal free light chain (FLC) ratio. Patients should be followed with serum protein electrophoresis at six months and, if stable, can be followed every 2–3 years or when symptoms suggestive of a plasma cell malignancy arise. Patients with intermediate and high-risk MGUS should be followed in 6 months and then annually for life. The risk of smoldering (asymptomatic) multiple myeloma (SMM) progressing to multiple myeloma or a related disorder is 10% per year for the first 5 years, 3% per year for the next 5 years and …
Total citations
Scholar articles
RA Kyle, BGM Durie, SV Rajkumar, O Landgren… - Leukemia, 2010